Anavex slips after CEO transition

2026-05-06 10:29:15 ET More on Anavex Life Sciences Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory Anavex Life Sciences Corp. (AVXL) Q1 2026 Earnings Call Transcript Anavex drops after pulling EU marketing application for Alzheimer's therapy Anavex outlines regulatory milestones for blarcamesine in 2026 while advancing ACCESS-AD participation Seeking Alpha's Quant Rating on Anavex Life Sciences Read the full article on Seeking Alpha For further details see: Anavex slips after CEO transition